Sarah M Meng takes an evidence-based approach and is stringent about sterile practices. She maintains a keen eye on aseptic techniques, gowning practices, and environmental monitoring, and expects well-documented compliance in these areas. Her focus on the segregation of beta-lactam drugs signifies her in-depth understanding of cross-contamination norms.

FDA Auditor Sarah M Meng seems to highly prioritize cleanliness and sterile practices in her audits. She tends to pay close analytical attention to critical areas like aseptic techniques, gowning practices, and environmental monitoring. Her insistence on validation data, especially for cleaning practices, suggests she has an evidence-based approach and seeks concrete proof of compliance with FDA regulations. In addition, her keenness on separation of specific drug processing facilities indicates a thorough understanding and adherence to cross-contamination prevention norms.